BeiGene Ltd
(FRA:49BA)
€
152
5 (3.4%)
Market Cap: 15.89 Bil
Enterprise Value: 14.29 Bil
PE Ratio: 0
PB Ratio: 5.23
GF Score: 69/100 - Beigene Ltd at JPMorgan Healthcare Conference TranscriptJan 08, 2024
- Beigene Ltd Investors and Analysts Panel Event Presentation TranscriptDec 11, 2023
- Beigene Ltd at Morgan Stanley Global Healthcare Conference TranscriptSep 11, 2023
- Beigene Ltd Investor Research and Development Day TranscriptJul 18, 2023
- Beigene Ltd at Goldman Sachs Global Healthcare Conference TranscriptJun 12, 2023
- Beigene Ltd at JPMorgan Healthcare Conference TranscriptJan 09, 2023
- Beigene Ltd to Discuss Final Results of the ALPINE Trial Late-Breaker Presentation TranscriptDec 13, 2022
- Beigene Ltd to Discuss Final Results of the ALPINE Trial Q&A Call TranscriptDec 12, 2022
- Beigene Ltd at Morgan Stanley Global Healthcare Conference TranscriptSep 14, 2022
- Beigene Ltd at Goldman Sachs Global Healthcare Conference TranscriptJun 14, 2022
- Beigene Ltd at Cowen Health Care Conference (Virtual) TranscriptMar 07, 2022
- Beigene Ltd at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) TranscriptFeb 10, 2022
- Beigene Ltd at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2022
- Beigene Ltd R&D Day TranscriptAug 25, 2021
- Beigene Ltd to Discuss Interim Analysis of the ALPINE Trial and Data Presented at EHA2021 Call TranscriptJun 11, 2021
- Beigene Ltd at JPMorgan Healthcare Conference (Virtual) TranscriptJan 14, 2021
- Beigene Ltd China National Reimbursement Drug List (NRDL) Results Conference Call TranscriptDec 29, 2020
- Beigene Ltd at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 17, 2020
- Beigene Ltd to Discuss the Company's Early Development Pipeline and Research Call TranscriptJul 09, 2020
- Beigene Ltd at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2020
- Beigene Ltd at American Society of Clinical Oncology (ASCO) Virtual Scientific Program Call TranscriptMay 30, 2020
- Beigene Ltd at JPMorgan Healthcare Conference TranscriptJan 15, 2020
- Beigene Ltd Update Call: ASPEN Trial Readout TranscriptDec 16, 2019
- Beigene Ltd Corporate Update: Global Strategic Oncology Collaboration with Amgen TranscriptNov 01, 2019
- Beigene Ltd at Morgan Stanley Healthcare Conference TranscriptSep 10, 2019
- Beigene Ltd Update Call TranscriptSep 08, 2019
- Beigene Ltd Conference Call to Discuss Clinical Data on Zanubrutinib at 15th International Conference on Malignant Lymphoma (ICML) TranscriptJun 20, 2019
- Beigene Ltd at Goldman Sachs Global Healthcare Conference TranscriptJun 12, 2019
- Beigene Ltd at Barclays Global Healthcare Conference TranscriptMar 13, 2019
- Q4 2018 Beigene Ltd Earnings Call TranscriptFeb 27, 2019€122.52 (+0.96%)Earnings
Beigene Ltd to Discuss Final Results of the ALPINE Trial Late-Breaker Presentation Transcript
Dec 13, 2022 / 08:00PM GMT
Release Date Price:
€196
(+7.10%)
Operator
Presentation
Dec 13, 2022 / 08:00PM GMT
=====================
Corporate Participants
=====================
* John V. Oyler
BeiGene, Ltd. - Co-Founder, Executive Chairman & CEO
* Josh Neiman
BeiGene, Ltd. - Senior VP, Chief Commercial Officer of North America & Europe
* Kevin C. Mannix
BeiGene, Ltd. - SVP of IR.
* Mehrdad Mobasher
BeiGene, Ltd. - Chief Medical Officer of Hematology
=====================
Conference Call Participants
=====================
* Andrew Scott Berens
SVB Securities LLC, Research Division - Senior MD of Medical Supplies and Devices & Senior Research Analyst
* Jennifer Brown
* Mazyar Shadman
=====================
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)